Efficacy of tibolone [Org OD 14; Organon] and raloxifene [Evista; Eli Lilly] or the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women at least 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial.

Trial Profile

Efficacy of tibolone [Org OD 14; Organon] and raloxifene [Evista; Eli Lilly] or the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women at least 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2010

At a glance

  • Drugs Raloxifene (Primary) ; Tibolone (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2010 Actual number of patients changed from 318 to 324 as reported by Netherlands Trial Register record.
    • 10 May 2010 Status changed from active, no longer recruiting to completed as reported by Netherlands Trial Register record.
    • 02 May 2009 New source identified and integrated (Netherlands Trial Register No. NTR1232).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top